Identification | Back Directory | [Name]
Cerdulatinib HCl salt | [CAS]
1369761-01-2 | [Synonyms]
Cerdulatinib HCl Cerdulatinib HCl salt PRT2070 hydrochloride PRT062070 hydrochloride Cerdulatinib hydrochloride Cerdulatinib HCl salt USP/EP/BP Cerdulatinib (PRT062070, PRT2070) 4-(cyclopropylamino)-2-[[4-[4-(ethylsulfonyl)-1-piperazinyl]phenyl]amino]-5-pyrimidinecarboxamide,hydrochloride (1:1) | [Molecular Formula]
C20H28ClN7O3S | [MDL Number]
MFCD28348366 | [MOL File]
1369761-01-2.mol | [Molecular Weight]
481.999 |
Chemical Properties | Back Directory | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO:20.0(Max Conc. mg/mL);41.49(Max Conc. mM) | [form ]
Solid | [color ]
Light brown to brown |
Hazard Information | Back Directory | [Biological Activity]
Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an orally active multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 for JAK1/JAK2/JAK3/TYK2 and Syk, respectively nM and 32 nM. Also inhibits 19 other kinases tested with IC50s below 200 nM. | [in vitro]
Cerdulatinib affects BCR-mediated B cell activation through dual inhibition of SYK and JAK in human whole blood from normal donors. As a dual SYK/JAK inhibitor, Cerdulatinib significantly reduced cell viability in a subset of NHL cell lines and induced apoptosis in NHL cell lines with BCR signaling. | [in vivo]
In a rat collagen-induced arthritis model, Cerdulatinib (5 mg/kg po) significantly improved inflammatory infiltration of synovium and articular cartilage integrity. In addition, cerdulatinib also blocked BCR-induced B cell activation and splenomegaly in mice. | [target]
Target | Value | TYK2 (Cell-free assay) | 0.5 nM | MST1 (Cell-free assay) | 4 nM | < td style="border-bottom: 1px dotted #ccc;padding: 5px;"> ARK5 (Cell-free assay) 4 nM | MLK1 (Cell-free assay) td> | 5 nM | Fms (Cell-free assay) | 5 nM |
|
|
Company Name: |
BOC Sciences
|
Tel: |
16314854226 |
Website: |
www.bocsci.com |
|